Five carbonate derivatives of 5´-O-2´,3´-dideoxyinosine (DDI, 1) have been synthesized by combination with aliphatic alcohols, with their in vitro anti-HIV activity and cytotoxicity, being afterward evaluated in human peripheral blood mononuclear cells (PBMCs). One particular compound, namely DDI-Penta exhibited an outstanding performance because it was found to have both a higher inhibitory potency and a lower cytotoxicity than the lead compound, resulting in a 100x enhancement in its selectivity index. In order to further study this phenomenon, the ability of these derivatives to bind to the cytoplasmic 5'-nucleotidase (ncN-II) was studied by in-silico methods. Also, the higher calculated lipophilicity of the synthesized compounds was proposed to improve their permeability through the cell membrane since said lipophilicity would allow a higher concentration of the corresponding prodrug inside the infected cell. Overall, a combination of an optimal lipophilicity and the ability of DDI-Penta to bind to ncN-II are suggested due to the higher potency and lower cytotoxicity observed for this compound. Based on the reported findings, we believe that the combination of certain aliphatic alcohols and DDI through a carbonate linkage could significantly increase the performance of this class of therapeutic compounds; therefore, it merits further evaluations.
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Introduction
Since first reported in the 1980s, type-1 human immunodeficiency virus (HIV-1) has spread rapidly through the human population and become one of the most devastating infectious agents facing mankind.
1-2 HIV-1 is the etiologic agent that causes Acquired Immunodeficiency Syndrome (AIDS)
which results in life-threatening opportunistic infections and malignancies. The increasing incidence of resistance to anti-HIV drugs together with many serious side effects and long-term complications for patients decrease the efficacy of the therapeutic compounds currently in use, which justifies the search for novel antiviral agents. [1] [2] Didanosine (2´,3´-dideoxyinosine, DDI, Figure 1 .a) is a nucleoside reverse transcriptase inhibitor (NRTI), 3 which is usually used in combination with other antiviral agents like zidovudine (AZT, Figure   1 .b) and lamivudine (3TC, Figure 1 .c) in the Highly Active Antiretroviral Therapy (HAART) against HIV-1 infection in adults. After reaching the cell cytoplasm, DDI is first phosphorylated by a nucleotidase enzyme to form DDI-5'-monophosphate (DDI-MP), 4 with 5'-nucleotidase ncN-II (ncN-II)
identified as the main protein isoform involved that has been vastly characterized and studied from a biochemical and structural point of view. [5] [6] In a second step, DDI-MP is converted to dideoxyadenosine-5'-monophosphate (DDA-MP) by adenylosuccinate synthetase and lyase, with subsequent phosphorylation to DDA-5'-triphosphate (DDA-TP) by adenylate kinase (miokinase).
DDA-TP constitutes the active metabolite that is responsible for the inhibition of the viral reverse transcriptase, acting as a competitive inhibitor or alternative substrate unlike the normal ones which leads to the termination of viral DNA chain elongation. [7] [8] [9] However, DDI exhibits several pharmacokinetic disadvantages like short plasma half-life (≈ 1h), relative low bioavailability, and a limited penetration into the central nervous system. [10] [11] [12] Figure 1. Chemical structures of: a) didanosine (DDI), b) zidovudine (AZT) and c) lamivudine (3TC).
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The design of prodrugs is one of the methods selected to improve the anti-HIV efficacy of a drug molecule by enhancing its spectrum of chemotherapeutic properties for the effective treatment of AIDS. The mentioned prodrugs would lead to a major distribution and retention of the parent compound in the body for a longer time. [13] [14] [15] Thus, the prodrugs have been rationally designed to decrease the toxicity associated with nucleoside drugs, to release active species from their degradative metabolisms and to allow larger amounts of drug to enter the cell. 13, [16] [17] [18] [19] [20] Although several DDI prodrugs have been prepared and evaluated in vitro and in vivo to overcome some of these problems, none of them are currently in routine clinical use. 21 Many nucleoside analogues with interesting biological properties have been developed by substitution at the 5'-O position of the NRTI with lipophilic chemical moieties linked by enzymatically hydrolysable functions such as ester and carbonate bonds. [19] [20] [21] [22] [23] [24] [25] [26] [27] The lipophilic character of the side chains at the 5´-O position should influence their ability to cross the cell membrane by passive diffusion, which is a key feature in the absence of an active nucleoside transport system. [22] [23] [24] [28] [29] As stated by Parang et al, 20 more selective compounds can be designed by using the strategy of 5'-Ocarbonates substitution. Although the clinical application of these approaches remains unknown, they hold the promise of becoming an important tool in the treatment of HIV infection and its related consequences.
Recently, we synthesized and evaluated the anti-HIV activity of carbonate prodrugs of lamivudine (3TC) with the aim of generating 3TC derivatives that were able to suppress HIV-replication more efficiently than its parent drug, with some promising results being reported. 30 Therefore, as part of our ongoing efforts to search novel antiviral agents, 28, [30] [31] [32] [33] [34] we also used the 5'-O-carbonate substitution strategy to link the aliphatic alcohols on the 5´-O position of DDI in order to enhance their lipophilicity, to facilitate their diffusion through the cell membrane independently of the nucleoside transport system, and to improve the in vitro anti-HIV activity of DDI.
35-36

Results and Discussion
Chemistry
Since the synthesis of 3TC prodrugs with ethanol, n-butanol, n-pentanol and n-hexanol moieties has previously demonstrated to be the most active compounds of the series against HIV 30 and HBV 37 viruses, in this work the synthetic protocols were extended to obtain the corresponding prodrugs of DDI. In addition, the synthesis of the prodrug including n-heptanol is first reported with the aim of including an additional methyl moiety in the explored series of n-alcohols.
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Taking into account that didanosine (DDI, 1, Figure 2 ) has one primary reactive functional group such as 5'-OH, an imidazole carboxylic ester, N, N-carbonyldiimidazole (CDI, 2, Figure 2 ) was used in the controlled and selective formation of carbonate derivatives of DDI. Thus, in the current study, our synthesis strategy was focused on the association of 5´-OH of DDI with the selected aliphatic alcohols. [29] [30] 36 This strategy was achieved in a two-step reaction sequence ( Figure 2 ). The didanosine intermediate named DDI-5'-CI (3, Figure 2 ) was obtained in quantitative yields by refluxing DDI with CDI in a dry mixture with dimethylformamide (DMF) at 40 °C for one hour.
As figure 2 shows, the in situ reaction of DDI-5'-CI with the respective aliphatic alcohols, ethanol, nbutanol, n-pentanol, n-hexanol and n-heptanol then gave the corresponding carbonates in 80-95%
(DDI-Hexa, 7) and 2´,3´-dideoxyinosine-5´-yl O-heptyl (DDI-Hepta, 8) carbonates, respectively. In all cases, unreacted DDI and CDI were not detected from the reaction media.
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The reaction proceeds via the formation of an imidazole anhydride intermediate which decomposes after either intra-or internucleophilic attack by an imidazole group of CDI, as proposed by Rannard et al. [38] [39] The purity of the synthesized compounds was checked by TLC and HPLC, and the structure of the resulting nucleoside derivatives 4-8 was identified by spectroscopic techniques such as 1 H-NMR, 13 C-NMR, DEPT 135 and COSY homo and heteronuclear spectra of 4-8, being performed in DMSO- In the IR spectra of 4-8, characteristic vibrational regions of the structural features were found. 40 The intensive absorption at 1690 cm -1 and 1744 cm -1 indicated the presence of carbonyl groups and the characteristic stretching of the carbonate moiety, respectively, as well as the characteristic of conjugation with the purine base. The hydrogen stretching region exhibits a broad band due to NH stretching bands and small C-H stretching bands. Other strong bands are the C-N stretching band at 1200 cm -1 and the C-O-C stretch of tetrahydrofurfuryl alcohol.
Antiviral and cytotoxicity evaluation
As previously described, In uninfected PBMCs, the values of CCID 50 for the studied prodrugs followed the order: DDI < DDI-Hexa< DDI-Buta< DDI-Hepta< DDI-Etha< DDI-Penta. These compounds showed CCID 50 values similar or slightly higher to that of the parent drug. It is important to point out that DDI-Penta exhibited a marked increase in its CCID 50 (≈ 70-fold) compared to DDI, which indicates that this compound is significantly less cytotoxic than the parent drug. As regards IC 50 values, DDI-Penta and DDI-Hexa exhibited similar antiviral potencies to DDI (i.e. showed similar IC 50 ), while the rest of the derivatives showed higher IC 50 values. In turn, the SI values calculated for all the prodrugs were similar to that of DDI, with the exception of DDI-Penta for which a 100-fold higher SI was observed. This result is mainly driven by a combined high antiviral potency and a marked decrease in its cytotoxic effect, suggesting a selective and effective bioactivation of this particular prodrug within the PBMC cell.
In order to further characterize the anti HIV performance of DDI-Penta, its anti-HIV activity was evaluated in PBMCs infected with wild type (WT) and NRTI-resistant primary viral isolates (see Experimental section for details). The calculated IC 50 and fold resistance (Fold-R!) values for DDI-
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Penta and the parent drug were both similar ( Figure 4 , Table 2 ) when using WT or NRTI-resistant primary isolates. This indicates that DDI-Penta maintains similar antiviral effect against HIV laboratory-adapted and primary strains with less cytotoxicity if compared to DDI. As will be supported later in this manuscript, the above commented observations merit the continuity of the investigation into this derivative. 
Molecular modeling studies
Molecular docking
To further study, if the anti-HIV performances of the prodrugs were related to their ratio of phosphorylation, the interaction with the enzyme ncN-II could be studied by molecular docking methods. Besides, the binding of DDI in its monophosphorylated form (DDI-MP) and that of the reported inhibitor AdiS were also analyzed and used as reference compounds. Table 3 shows the docking rank obtained together with the corresponding energetic components for the intermolecular interaction as calculated by the Chemgauss4 force field. Table 3 . Energetic components derived from the molecular docking of the studied compounds.
As can be seen in table 3, DDI-MP exhibited the highest affinity for ncN-II (i.e. it was the first ranked ligand) which is in some way expected since this is the compound formed by the enzyme. When the energetic components were analyzed, a high stabilization derived from electrostatic interactions (-9.39) was calculated, while a minor contribution from van der Waals contacts (-6.39) was found. As 
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VdW contribution. Finally, it is noteworthy that the AdiS inhibitor ranked in the last place among the whole set of compounds (Figure 6 .d). The results obtained by molecular docking suggest that the newly synthesized prodrugs of DDI are able to occupy the catalytic site of ncN-II, establishing an intermolecular interaction with key aminoacid residues.
The above commented results have confirmed that the prodrugs of DDI can fit into the catalytic site of ncN-II; however, the rigid-body molecular docking techniques are not precise enough to definitively assess the time-dependent conformation of the studied inclusion complex and the corresponding evolution of intermolecular forces involved. [41] [42] Although the docking methods are very powerful to predict the initial pose of the complex, they may then be subjected to further refinement by molecular dynamics methods, in which the flexibility of cnN-II is taken into account and the effect of temperature and solvent can also be modeled.
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Analysis of MD trajectories
After obtaining the corresponding MD production runs for the ligands: ncN-II complexes, their quality was checked by evaluation of their potential, kinetic and total energies (plots not shown).
Structural properties were also measured in order to asses if the studied ligands remained bound into the corresponding binding site, with values of their root mean square deviation (RMSD) indicating that in all cases the ligand:cnN-II complexes remained stable throughout the simulated time (1 ns). Table 4 . Energetic decomposition analysis and component values derived from the molecular dynamics simulations of the studied compounds.
Conclusion
The synthesis of five 5´-O-2´,3´-dideoxydidanosine prodrugs with the further quantitation of their in vitro anti-HIV activity in PBMCs and associated cytotoxicity has been described. These studies have shown the utility of the carbonate linkage in creating prodrugs from DDI and also indicated how the physical-chemical properties of this drug have been substantially modified to produce different compounds with increased lipophilicities and good antiviral performance (inhibitory potency and low cytotoxicity).
The outstanding increase in the selective index of DDI-Penta compared to that of the parent drug could be related to the ability of this prodrug to efficiently bind to ncN-II, which would in turn generate higher intracellular levels of DDI-MP. Besides, based on their higher calculated lipophilicities, we believe that an improved permeability through the cell membrane would aid in reaching higher concentrations of these prodrugs within the target cells.
Founded on the above commented aspects, the use of a carbonate linkage at the 5'-OH position of DDI combined with the use of n-alcohols appears to be a very promising strategy to enhance the potency and security of this NRTI. Among the studied prodrugs, DDI-Penta outstands as the most promising candidate for further evaluations. 
Materials and Methods
Chemistry
All chemicals, reagents and solvents were of analytical grade. 
2´,3´-dideoxyinosine-5´-yl O-butyl carbonate (5, DDI-Buta)
In accordance with the general procedure, by adding n-butanol (0.239 mL, 2.617 mmol, 3 eq.), the title compound 5 was obtained as a white solid. Yield: 257 mg (90%); R f : 0.56; MW: 336.2. 
2´,3´-dideoxyinosine-5´-yl O-pentyl carbonate (6, DDI-Penta)
In line with the general procedure, by adding n-pentanol (0.284 mL, 2.617 mmol, 3 eq.), the title compound 6 was obtained as a white solid. Yield: 279 mg (94%); R f : 0.59; MW: 350.2.
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2´,3´-dideoxyinosine-5´-yl O-hexyl carbonate (7, DDI-Hexa)
According to the general procedure, the addition of n-hexanol (0.327 mL, 2.617 mmol, 3 eq.)
afforded the title compound 7 as a white solid. Yield: 271 mg (88 %); R f : 0.63; MW: 364.2. 
2´,3´-dideoxyinosine-5´-yl O-heptylcarbonate (8, DDI-Hepta)
In agreement with the general procedure, the addition of n-heptanol (0.366 mL, 2.617 mmol, 3 eq.)
afforded the title compound 8 as a white solid. Yield: 256 mg (80 %); R f : 0.65; MW: 378.2. 
Antiviral activity and cytotoxicity assays
PBMCs were infected at 6.45×10 5 TCID 50 /10 6 cells for 2 h at 37°C. After infection, cells were washed and dispensed in a 96-well plate in the presence of 10-fold serial dilutions of compounds. The experiments were performed in triplicate. Untreated wells and wells treated with DDI were also monitored as controls of antiviral activity. Culture medium was changed on the fourth day maintaining the original concentration of the drug. On the seventh day, supernatant fluids were harvested and production of p24 antigen was subsequently evaluated using a commercial enzyme linked immunosorbent assay (ELISA) (Vironostika, The Netherlands). Based on p24 quantitation, the dose that inhibited 50% of the viral production (IC 50 ) was determined.
Cytotoxicity studies on uninfected PBMCs were performed in parallel in order to determine the concentration of the drug that inhibited 50% of cell growth (CCID 50 Results obtained in cultures treated with AZT are also shown as reference.
Molecular modeling studies
Molecular docking
The structures corresponding to the studied ligands were constructed using the Gabedit graphical interface, 44 and were afterwards subjected to energy minimization using semi-empirical and ab-initio methods as implemented in the Gaussian03 package. 45 The minimum energy conformation was then subjected to ionization and tautomers analysis considering a pH of 7.0 by applying the algorithms implemented in the MOKA software (Molecular Discovery Ltd.), [46] [47] with the resulting structure being used as a starting point to generate a conformer database intended for the rigid-body docking protocols.
The OMEGA software was used to generate this database, 48-49 applying an energy threshold of 10 Kcal and assigning BCC system charges to each conformer to model the corresponding intermolecular forces during docking runs.
The receptor model used for docking assays corresponded to the crystal structure of ncN-II in complex with an anthraquinone derived inhibitor (AdiS), which has been recently reported by Jordheimet al. 6 The structure was retrieved from the Protein Databank (pdb code: 4H4B). Before performing the docking runs, crystallographic water molecules present in a 6Å radius from the ligand were retained. A docking box of 10000 Å 3 was generated and centered on AdiS, with standard ionization states being considered for the rest of the protein.
The ligands conformer libraries were docked to the above mentioned receptor using a fast rigid exhaustive docking approach as implemented in the FRED software, [50] [51] with the corresponding docked poses being scored using the Chemgauss4 function as implemented in the software package.
The lowest energy binding pose was selected, analyzed and subjected to posterior molecular dynamics (MD) studies. Visualization and analysis of intermolecular interactions were performed using the VIDA, VMD and LigPlus software packages.
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Molecular dynamics (MD) simulations
MD simulations were performed using the Amber12 software package. 54 Charges and parameters of ligands were assigned from the GAFF atomic force-field, 55 while the parameters for the receptor corresponded to the ff03ua force field. 56 Initial coordinates of the corresponding complexes were obtained by the molecular docking procedures described above, and simulated under implicit solvent conditions. The protocol applied included the following stages: a) minimization stage (10000 steps), b)
heating phase (20 ps, target temperature 300 K) performed under constant volume conditions, c) an equilibration step (200 ps) at constant volume and temperature (300 K) conditions and finally d) a production run (1 ns) obtained at constant pressure and temperature (300 K). In all cases, an integration time step of 2 fs was used applying the SHAKE algorithm to restrain the bonds involving the hydrogen atoms. Analysis over the MD trajectories were applied using the Ccptraj module of Amber12, while total and per-residue energetic decomposition analysis were performed using the Molecular Mechanics
Poisson-Bolzmann Surface Area (MM-PBSA) approach. Gloria Bonetto's assistance in NMR data analyses is also gratefully acknowledged.
